Oktober 1993 – Research Fellow am Center for Neurologic Diseases,
Oktober 1994 – Brigham and Women´s Hospital (H.L.Weiner), Harvard Medical School, Boston, USA,
November 1995 – Wissenschaftlicher Assistent, Institut Anatomie,
Dezember 1995 – Universität Köln (Prof. Dr. K. Addicks)
Januar 1996 – AiP/Assistenzarzt, Medizinische Universitätsklinik
März 1999 Freiburg, Hämatologie/Onkologie (Prof. R. Mertelsmann)
November 1997 – Promotion Medizin, Universität Köln
Mai 1999 – Postdoc, Dept.of Pathology (T. Gajewski), University of
August 2002 – Chicago, Chicago, USA
September 2002 – Assistenzarzt, Medizinische Universitätsklinik Freiburg,
September 2007 – Hämatologie/Onkologie (Prof. R. Mertelsmann)
Juni 2007 – Facharzt Innere Medizin
seit Oktober 2007 – Oberarzt, Medizinische Universitätsklinik Freiburg, Hämatologie/Onkologie (Prof. R. Mertelsmann)
seit Januar 2009 – zusätzlich Oberarzt, Center of Chronic Immundeficiency (CCI), Medizinische Universitätsklinik Freiburg,
12. Februar 2009 – Habilitation (Venia legendi) in Innerer Medizin, Universität Freiburg
Marks R., Fan W., Engelhardt M., Veelken H., Finke J.
Medizinische Universitätsklinik Freiburg, Hämatologie/Onkologie, Freiburg, Germany
Introduction: Since no standard therapy exists, CHOP-like therapies are commonly used as therapy for T-NHL. The impact of early dose intensification with high-dose therapy and autologous stem cell transplantation (ASCT) is less well defined.
Methods: We present retrospective longterm follow up data from a single center using response adapted early dose intensification and first line ASCT in patients with T-NHL.
Results: From 12/1986-07/2009 a total of 113 patients were treated. The median age was 56 years (range: 18-90), the diagnoses included: PTCL,NOS (n=46), AITL (n=25), ALCL,ALK negativ (n=26), ALCL,ALK positiv (n=7), and others (n=11). Initial chemotherapy included anthracycline based/CHOP-like regimens in most of the cases. If no complete remission (CR) could be achieved by CHOP-like induction, early intensification, mainly with VIPE/VCPE (epirubicin 50mg/m2 , etoposide 500mg/m2 , cisplatin 50mg/m2 , ifosfamide 4g/m2 or cyclophosphamide 1350mg/m2) or DHAP regimens, and ASCT after BEAM conditioning (66.6% of all ASCT) was initiated. 5-year overall survival (OS) of the entire group was 53,1% (median follow-up: 59.7 months). 5y-OS were 62,8% for patients with PTCL,NOS, 45,1% (AITL) and 48,6% (ALCL, ALK neg.). In PTCL,NOS patients 31/46 (68,9%) experienced a CR1 after primary therapy. Of those 31 patients, CR was achieved after CHOP-like induction in 18 and after intensification in additional 3 cases, while the remaining 10 patients experienced CR only after ASCT. 5 year-relapse rate (RR) for patients in CR was significantly worse for patients not undergoing ASCT (68,0% v. 15,6%, p=0,0046) with relapses occurring up to 4 years after completion of standard dose therapy. Nevertheless, primary therapy with ASCT did not result in significantly improved 5y-OS compared to patients without ASCT (64,6% v. 60,1%), mainly due to longterm disease control with second line ASCT in some patients relapsed after standard therapy. Similar results were observed in patients with ALCL, ALK neg.: 5y-OS with/without primary ASCT was 60,8% v. 38,5% (p=0.64); cumulative 5-y RR for patients in CR1 was 11,1% v. 40,0% (p=0.26). In contrast, in AITL patients treatment with ASCT resulted in a significantly improved 5-y OS (87,5% v. 21,8%, p=0.01). Conclusion: Primary ASCT results in improved disease control in T-NHL. Nevertheless, less well understood heterogeneity of lymphoma biology might be of more importance for the treatment outcome than dose intensity.